Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

Michael Caligiuri, MD, discusses the modulation of natural killer cells to enhance their ability to detect and destroy tumor cells.

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo ...

Solid tumor CAR-NK targets NKG2D and NKG2D ligands. By connecting with its tumor-associated overexpression ligands, such as MICA, MICB, and ULBPs, NKG2D, an activating NK cell receptor can ...

Ex vivo expanded NK cells were electroporated with mRNA (4 µg/10 6 NK cells) encoding the high-affinity, CD16-158V Fc receptor. NK cell CD16 expression was measured via flow cytometry for 72 ...

Researchers at the VIB-KU Leuven Center for Cancer Biology have uncovered that "natural killer" cells (NK), a type of immune cell, may actually be hindering the immune system's ability to attack ...

GICELL announced the data from the preclinical studies on T.O.P. NK therapy at the Society for Immunotherapy of Cancer that was held in Boston.

Aggressive natural killer cell leukemia (ANKL) is a rare and aggressive type of blood cancer that affects white blood cells called “natural killer (NK) cells”.